Search


Accessing new eye therapies, protecting vision, improving patients' comfort, developing breaktrough treatments

Home

Novagali Pharma - Accessing new eye Therapies

Novagali Pharma is an emerging ophthalmic pharmaceutical company that develops innovative products for all segments of the eye.

The company has developed a broad pipeline of innovative products addressing main ocular conditions as well as orphan diseases, thanks to its proprietary technology platforms Novasorb® and Eyeject®.

Press Release

EVRY-  May 05, 2009 - Novagali Pharma announces FDA Clearance of IND for phase III of Catioprost®, its cationic emulsion of Latanoprost in patients with Glaucoma Read more

 

 

EVRY – 15 April 2009 Novagali Pharma completed a new Phase II with Cyclokat® in dry eye.

Read more

Press Release

Siemens awardEVRY – 8 June 2009 Novagali Pharma receives the “Health Award” from Siemens for Novasorb®, its cationic emulsion proprietary technology platform.

Read more

 

Frost AwardEVRY-  March 19, 2009 - Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies, with the 2009 North American Frost & Sullivan Award for Industry Innovation & Advancement of the Year Read more

 

Discover Cationorm®

Cationorm

An innovative cationic emulsion to relieve dry eye sensation 

  • Moisturization
  • Lubrication
  • Protection

of the eye surface

 Read more

 

Accessibility Focus

Our commitment to make our site accessible to anyone is based on the WCAG standards. Would you have any suggestion or request do not hesitate to contact us: Make a suggestion.



Choose your language